Rekombinanter TNF alpha (Infliximab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter TNF alpha (Infliximab Biosimilar) Antikörper (ABIN5668147)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-TNF alpha [cA2 (Infliximab)], Human IgG1, kappa
-
Spezifität
- Binds to soluble and transmembrane forms of TNF-alpha and neutralizes its biological activity. Does not bind to TNF-beta.
-
Produktmerkmale
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
Aufreinigung
- Protein A affinity purified
-
Reinheit
- > 98 % as determined by SDS-PAGE
-
Endotoxin-Niveau
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
-
Immunogen
- Purified recombinant human TNF (rTNF).
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
- This antibody can be used to detect and neutralize human TNF alpha. Unlike Adalimumab (Ab00718), Infliximab does not bind to mouse TNF alpha (Arnoult 2017, PMID: 28584008).
-
Kommentare
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS with 0.02 % Proclin 300.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- TNF alpha (Infliximab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- TNF-α, TNFα, TNFSF, Tumor necrosis factor, Cachectin, TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a, TNFa
-
UniProt
- P01375
Target
-